TeleFlex Banks on Urolift Sales Amid Coronavirus-Led Debacle

On Aug 21, we issued an updated research report on Teleflex Incorporated TFX. The company has been witnessing a solid uptick in revenues, driven by sturdy performance across the majority of segments and geographies. However, escalating costs and expenses remain a major cause of worry. The stock currently carries a Zacks Rank #3 (Hold).

Over the past six months, Teleflex’s stock has underperformed its industry. The stock has gained 2.5% compared with the industry's 15.5% growth. 

In the second quarter of 2020, on a year-over year basis, earnings and sales both declined significantly. Most of the segments registered organic revenue decline on a 20% aggregated negative impact of COVID-19. The company’s Asia business experienced a revenue decline due to COVID-19.

The Interventional business revenues were hampered due to the cancellation of certain non-emergent procedures whereas Anesthesia segment saw lower sales of laryngeal masks and certain regional Anesthesia products. Shutdown of one of the company’s third-party sterilization providers during the quarter was also concerning. This time too the company did not provide its 2020 guidance.

Teleflex Incorporated Price

Teleflex Incorporated Price

Teleflex Incorporated price | Teleflex Incorporated Quote

On a positive note, underlying business, without considering the pandemic impact, grew approximately 8% at CER. Growth within the Americas was driven by strong sales of Vascular Access and respiratory products, both of which saw coronavirus-led elevated demand.

NeoTract, the acquired business of Teleflex, has been performing impressively lately. This has prompted Teleflex to pay a higher level of contingent consideration than previously planned. Notably, UroLift System is a minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia.

In the second quarter, Urolift sales were down but there was a gradual improvement in the monthly sales trend. From April’s 80% dip, in May, the decline was just 30%.

Stocks to Consider

Some better-ranked stocks from the broader medical space are QIAGEN N.V. QGEN, Thermo Fisher Scientific Inc. TMO and Hologic, Inc. HOLX.

QIAGEN’s long-term earnings growth rate is estimated at 22.3%. It currently sports a Zacks Rank #1. (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Thermo Fisher’s long-term earnings growth rate is estimated at 15%. It currently carries a Zacks Rank #2 (Buy).

Hologic’s long-term earnings growth rate is estimated at 15.5%. The company presently sports a Zacks Rank #1.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hologic, Inc. (HOLX): Free Stock Analysis Report
QIAGEN N.V. (QGEN): Free Stock Analysis Report
Teleflex Incorporated (TFX): Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More